Stacey Knox, MD
Hematology & Oncology · Lincoln, NENPI 1750353447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $443 and has fallen 71.1% since, to $128 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 83 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$261
- Pharmacyclics LLC, An Abbvie Company$176
- AbbVie$138
- Bristol Myers Squibb$135
- Pfizer$86
- Array Biopharma Inc$83
- plus $579 from 19 others
Across 111 payments — averaging $5151.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$221K
- Pharmacyclics LLC, An Abbvie Company$158K
- E.r. Squibb & Sons, L.L.C.$103K
- Bristol Myers Squibb$57K
- Merck$14K
- AstraZeneca$13K
- plus $6K from 2 others
What the payments were for
- Food & beverage$1,44699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $261 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $176 |
| AbbVie | 6 | $138 |
| Bristol Myers Squibb | 8 | $135 |
| Pfizer | 9 | $86 |
| Array Biopharma Inc | 4 | $83 |
| Daiichi Sankyo Inc. | 2 | $56 |
| EMD Serono, Inc. | 3 | $55 |
| CTI Biopharma Corp. | 3 | $48 |
| GSK | 3 | $45 |
| Novartis | 2 | $42 |
| AVEO Pharmaceuticals, Inc. | 1 | $40 |
| AstraZeneca(2 entities) | 2 | $38 |
| Eisai Inc. | 2 | $37 |
| Merck | 3 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Seagen Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Morphosys, US Inc. | 1 | $21 |
| Incyte Corporation | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $15 |
| Adaptive Biotechnologies Corporation | 1 | $13 |
| Novocure Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$1,458 in reported general payments places this provider in the 35th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 66 | $897,969 |
| RevlimidLenalidomide | 38 | $699,143 |
| IbrancePalbociclib | 29 | $473,275 |
| ImbruvicaIbrutinib | 29 | $452,043 |
| KisqaliRibociclib Succinate | 16 | $267,867 |
| TagrissoOsimertinib Mesylate | 11 | $173,255 |
| VenclextaVenetoclax | 11 | $153,957 |
| EliquisApixaban | 25 | $18,424 |
| XareltoRivaroxaban | 14 | $9,034 |
| Imatinib Mesylate | 23 | $7,989 |
| Letrozole | 236 | $3,185 |
| Hydroxyurea | 79 | $1,988 |
| CholestyramineCholestyramine (With Sugar) | 12 | $1,508 |
| Tamoxifen Citrate | 67 | $1,298 |
| Anastrozole | 50 | $662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $135 | $699,14338 claims |
| PfizerIbrance, Eliquis | $86 | $491,69954 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $176 | $452,04329 claims |
| NovartisKisqali | $42 | $267,86716 claims |
| AstraZenecaTagrisso | $38 | $173,25511 claims |
| AbbVieVenclexta | $138 | $153,95711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Lincoln
- Madhu MidathadaLincoln$24K
- Steven DunderLincoln$20K
- Kailash MosalpuriaLincoln$17K
- Nathan GreenLincoln$10K
- Melissa CetakLincoln$6K
- Eric AveryLincoln$6K
- Wallace PetersonLincoln$5K
- Amanda BauerLincoln$5K
- Joni TilfordLincoln$4K
- Kathleen TonkinLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.